Merck expects revenues to be in the range of $64.1-$65.6 billion in 2025, indicating year-over-year growth in the range of 2% ...

Merck's first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 adjusted earnings projection, partly to account for recently imposed ...

Merck said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the U.S. and China. The estimate doesn’t account for the possibility that ...

For 2025, Merck said it still expects sales of $64.1 billion to $65.6 billion, but it lowered its adjusted earnings per share forecast to between $8.82 and $8.97, from a previous $8.88 to $9.03.

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid an escalating trade war between the US and China, where demand for its blockbuster Gardasil vaccine is ...